AzTrials
AzTrials

Diabetic FootPhase 4NCT03209466

Chlorhexidine Gluconate Solution at 0.125% vs Placebo for the Healing of Grade IIB Ulcers of Diabetic Foot

A Phase 4 study testing Chlorhexidine gluconate at 0.125% in people with Diabetic Foot, run by Universidad de Guanajuato at 1 site in Mexico.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

There is controversy regarding the utility of antiseptics in wound management for diabetic foot ulcer syndrome. The aim of this study is to assess chlorhexidine gluconate at 0.125% vs. saline solution to reduce the ulcerated area in patients with diabetic ulcer syndrome. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetic Foot
What is being tested?
Chlorhexidine gluconate at 0.125%
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
35 participants
Where
1 siteMexico
Study dates
11 May 2017to 30 Dec 2020
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Ambulatory patients of both sex over age of 18 years old with diabetes mellitus that present an ulcer caused by diabetic foot syndrome with an extension from skin to tendon or join capsule and infected, classified as Texas IIB.

Who cannot join

  • Patients lost to follow up and those that voluntary leave the study.

Trial locations and contacts

1 site in 1 country.

Mexico1 site, 1 recruiting
  • Universidad de Guanajuato

    León, Guanajuato, 37320

    Juan M Muñoz, MD, jmunozb@me.com

    Recruiting

Other trials in Mexico

About this study

Official title: Standard Management and Chlorhexidine Gluconate Solution at 0.125% Versus Standard Management and Physiological Saline Sterile Solution for Healing Grade IIB Ulcers in Diabetic Foot Syndrome: Clinical Trial

There is controversy regarding the utility of antiseptics in wound management for diabetic foot ulcer syndrome. The aim of this study is to assess chlorhexidine gluconate at 0.125% vs. saline solution to reduce the ulcerated area in patients with diabetic ulcer syndrome. A clinical trial model to evaluate modifications in size and area is proposed. Patients to be included will be those with diabetic foot ulcers Graded II accordingly to the University of Texas wound classification system.

Read the detailed description

This study will be done in Hospital General de Leon

Population: People with diabetic foot syndrome grade IIb in Guanajuato Mexico

Universe: People with diabetes mellitus and diabetic foot syndrome in Guanajuato

Sample: Patients with diabetes mellitus over age of 18 years old, that present to the wound´s clinic of Hospital General Leon with diabetic foot ulcers classified as Texas IIB. This clinic provides services to patients in Guanajuato with diabetic foot syndrome, including them in a multidisciplinary management program.

Sample size calculation: A minimal sample of 35 patients for each arm of the study was calculated. Each study arm will be balanced considering the size. Potency was calculated at 0.8 and alpha value at 0-5, to detect a difference of 25% on the ulcer size.

Methodology:

Will be invited to participate in the study consecutive patients with diabetes mellitus presented with diabetic foot ulcers Graded II accordingly to the University of Texas wound classification system, in the area of Clinical wounds of Hospital General Leon between May and December 2017.

After explaining the study information and check it is understandable, the investigators provide the sheet to signed the informed consent.

Subsequently selected patients will be measure the ankle brachial index and determine the absence of vascular compromise.

Medical history with emphasis on analyzing clinical data, including the characteristics of the ulcer (type of exudate, measured surface area affected , type of tissue involved in the ulcer to its depth ) and biochemical parameters will be made.

Patients will be weighed and measured at the first visit and those who don't have biochemical data will be requested to collect this information in subsequent follow-up visits.

The participants will be then treated with the principles of the standard treatment, under the following criteria:

  • Remove the ulcer exudate by spraying one of the two ingredients making mechanical drive for 5 minutes, or until completely negative to the visual evidence of exudate.
  • Completely remove hyperkeratosis and devitalized tissue from the periphery of the ulcer with cutting material dissection with sterile dressing and drag, until visually eliminate the exudate.
  • The treated area is dried.
  • Two photographs at a distance of 20 cm perpendicular to the ulcer will be taken, covering a 1 square centimeter reference for measuring the area affected by diabetic foot ulcer syndrome.
  • The solution will be applied in a blinded way to the ulcer and covered with sterile gauze for 24 hours.
  • The patient will be instructed to continue treatment every 24 hours as follows:
  • Sterile gauze will be removed and continuously irrigate for 5 seconds with the ingredient that was assigned.
  • Undiscovered for 24 hours, until the next day irrigation gauze area will be placed. Also need to avoid contact with any surface over the affected area until the next assessment.
  • Perform the same strategy for 24 hours, and on day 7 must go to the wound clinic to clinical evaluation.
  • Every 7 days until complete 6 views, clinical evaluation is performed, irrigation with the selected ingredient and it will take 2 pictures at a distance of 20 cm perpendicular to the ulcer again, covering a reference of 1 square centimeter to measure the area affected by the diabetic foot ulcer syndrome.

Every week during the following 6 weeks, in the wound clinic consultation, it will be measured and gather information of the following elements:

  • Ulcer area in square millimeters.
  • Color of the ulcer.
  • Type of exudate; turbid, serous.
  • Type of tissue involved in the ulcer to its depth. If any patients have increased intensity of the signs and symptoms of diabetic foot syndrome, classified as a major step on the scale of ulcers Classification System of the University of Texas, perform analysis and comprehensive treatment will be redefined according to the suggestions of ulcer classification system of the University of Texas.

Cleaning material for the ulcer:

Ingredient 1: Preparation of spray application of chlorhexidine gluconate 0.125%.

Ingredient 2: Preparation of spray application of physiological saline sterile solution.

Method of application of ingredients as described previously. Method of randomization: will be effected since the fabrication of the ingredient by assigning a code number to each of the bottles that contained. Those bottles will have identical presentations, and will balance for the sample size. The code will not be known by the patient, observer and analyst. Only be known by one of the advisors.

Statistical methods:

The description of the data, in the case of non-numerical variables will be performed by reporting proportions and confidence interval of 95 % (95 %) in the case of numerical variables, the description will be made based on averages and standard deviation or medians and Q1- Q3 range, depending on the result of the Kolmogorov-Smirnov test to evaluate the Gaussian distribution of the data.

Comparison of numerical variables were not performed by Chi square test. Comparison of the rates of reduction in the size of ulcers of diabetic foot syndrome for both treatments will be based on the t test for independent samples or by Kruskal- Wallis test, depending on data distribution.

In all cases be considered as the significance level alpha value <0.05.

Conditions
Diabetic Foot
Being tested
Chlorhexidine gluconate at 0.125%, Placebo Comparator with physiological saline sterile solution
Keywords
Chlorhexidine gluconate, Diabetic foot ulcer syndrome, Wound healing
Medical subject headings
Diabetic Foot

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Chlorhexidine gluconate at 0.125%Drug

    Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate

  • Placebo Comparator with physiological saline sterile solutionDrug

    Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.

Study groups in NCT03209466
Study groupRoleWhat they receive
Standard management and Chlorhexidine gluconate at 0.125%ExperimentalApplication every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
Receives: Drug: Chlorhexidine gluconate at 0.125%
Standard management and physiological saline sterile solutionPlacebo comparatorApplication every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
Receives: Drug: Placebo Comparator with physiological saline sterile solution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Ulcerated area

    area of diabetic foot ulcer measured with photographic register using a visual control of dimensions and a dedicated software for measurements.

    Measured: Up to 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jul 2017
  2. Study start11 May 2017
  3. Primary completion15 Dec 2020 (estimated)
  4. Study completion30 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
35 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03209466
Sponsor's protocol ID
CHXDF
Status last verified
Mar 2019
First submitted
1 Jul 2017
Last updated
15 Mar 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: None IPD will be share; only group data analyzed

Publications

  • Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV; American College of Foot and Ankle Surgeons. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006 Sep-Oct;45(5 Suppl):S1-66. doi: 10.1016/S1067-2516(07)60001-5.

    PubMed 17280936
  • Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005 Nov 12;366(9498):1719-24. doi: 10.1016/S0140-6736(05)67698-2.

    PubMed 16291066
  • Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001 Jul 14;358(9276):135-8. doi: 10.1016/s0140-6736(01)05321-1.

    PubMed 11463434

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Chlorhexidine gluconate at 0.125% in people with Diabetic Foot, run by Universidad de Guanajuato at 1 site in Mexico.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jose A Alvarez, PhD (52 477 2674900 ext. 4643, alvarez_ja@me.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ulcerated area (time frame: Up to 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03209466, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2019; AzTrials last refreshed its copy on 31 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in